7th Eurasian Hematology Oncology Summit

 

Leukemia
07:30

7th Eurasian Hematology Oncology Summit

Rational Drug Use for Hematologic Malignancies: How Do We Define It? What Are the Obstacles? What Is the Role of Pharmacists?

FEATURING Mehmet Yilmaz
  • 12 views
  • December 16, 2020
14:53

7th Eurasian Hematology Oncology Summit

2020 Updates on MRD in Adult ALL: How Does MRD Help With the Assessment of Treatment Efficacy? What Are the Limitations? Is Guided MRD Feasible?

FEATURING Farhad Ravandi
  • 12 views
  • December 15, 2020
12:22

7th Eurasian Hematology Oncology Summit

2020 Updates on Frontline AML: Does Midostaurin+Chemo Reduce the Risk of Death in FLT3-Mutated Disease? Can We Prolong OS and Achieve CR With CPX-351? Is There a Way to Avoid Apoptosis With Ven+FLAI?

FEATURING Giovanni Martinelli
  • 17 views
  • December 11, 2020
23:15

7th Eurasian Hematology Oncology Summit

2020 Frontline CML Update: Comparing TKI Inhibitors, Achieving TFR in Clinical Practice

FEATURING Giuseppe Saglio
  • 89 views
  • December 11, 2020
15:13

7th Eurasian Hematology Oncology Summit

How I Treat Frontline CML in 2020: Does Imatinib Improve Long-Term Survival vs. Nilotinib? When Should We Adjust TKI Dose?

FEATURING Hagop Kantarjian
  • 478 views
  • December 11, 2020
  • 4
14:55

7th Eurasian Hematology Oncology Summit

How I Treat Frontline ALL in 2020: Does Ph-Like Disease Have a Higher MRD+ Rate? Is ChemoRx+/- Rituximab Beneficial for OS/EFS in Burkitt Disease? Do We Need AlloSCT?

FEATURING Hagop Kantarjian
  • 26 views
  • December 11, 2020
17:21

7th Eurasian Hematology Oncology Summit

2020 Update on MRD in AML: Does Decitabine Prolong RFS/OS in Newly Diagnosed Disease? Can Aza Help Achieve MRD Negativity? Is CC-486 Effective as Post-Remission Maintenance Therapy in Older Patients?

FEATURING Farhad Ravandi
  • 12 views
  • December 9, 2020
14:41

7th Eurasian Hematology Oncology Summit

How I Treat AML in 2020: Is Addition of Azacitidine to Venetoclax/Placebo Viable? How Effective Is Magrolimab + AZA Combo?

FEATURING Farhad Ravandi
  • 520 views
  • September 30, 2020
  • 1
21:52

7th Eurasian Hematology Oncology Summit

2020 Efficacy Data on Targeted Therapies in CLL: Do We Need to Combine Rituximab With Ibrutinib for Better PFS? How Does Venetoclax/Obinutuzumab Affect Survival Rates? What’s the Therapeutic Potential of Acalabrutinib?

FEATURING Panayiotis Panayiotidis
  • 83 views
  • September 28, 2020
18:04

7th Eurasian Hematology Oncology Summit

How I Treat CLL in 2020: How Do Ibrutinib/Rituximab & Venetoclax/Obinutuzumab Combinations Affect PFS? What Parameters Should Be Used to Guide the Treatment?

FEATURING Robin Foa
  • 200 views
  • September 28, 2020
  • 1